Nankai Univ. EGFRC797S compound 9ea

Nankai Univ. EGFRC797S compound 9ea: sourced facts only. name: "9ea was identified as the lead compound, demonstrating potent degradation of EGFRC797S and other main EGFR mutants (DC50 = 2.9 ± 1.1 nM, Dmax = 93.1 ± 6.5%)." [PMID:40640988]; target: "9ea was identified as the lead compound, demonstrating potent degradation of EGFRC797S and other main EGFR mutants (DC50 = 2.9 ± 1.1 nM, Dmax = 93.1 ± 6.5%)." [PMID:40640988]; developer: "School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China." [PMID:40640988]; modality: "These findings suggest that 9ea is a potent and selective EGFRC797S PROTAC degrader with potential for the treatment of EGFR mutant-driven NSCLC." [PMID:40640988]; stage: "In NSCLC (EGFRC797S) xenograft mouse models, 9ea significantly inhibited tumor growth (74.7% TGI @ 50 mg/kg) and effectively depleted EGFR proteins in tumor tissue." [PMID:40640988]